View Alert


Originator: DHSC & NHS England and Improvement: Supply disruption alert

 
Issue date: 29-May-2020 11:37:10

Action by recipients:
  • Care Trusts
  • Mental Health Trusts
  • Specialists Trusts
  • NHS Regional Offices
  • Learning Disabilities Trusts
  • Mental Health & Social Care Trusts
  • Ambulance Trusts
  • Mental Health & Learning Disabilities
  • Acute Trusts
  • Community Trusts

Information to recipients:
  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • GP - Locum
  • NHS 111 and Out of hours providers
  • GP Practices
  • DHSC Supply Disruption - Medicines
  • Primary Care Networks

Action category: Action

Title: Zyban (bupropion hydrochloride) 150mg prolonged release tablets - supply disruption

Broadcast content:
Zyban® (bupropion hydrochloride) 150mg prolonged release tablets will be out of stock from week commencing 15th June 2020 until the end of November 2020. 

Unlicensed supplies of bupropion 150mg prolonged release tablets have been sourced. 

Champix® (varenicline tartrate) tablets, which are licensed for the treatment of nicotine dependence, are available.

Various nicotine replacement therapies (NRT) are also available.

This alert contains advice on the management of affected patients.


Additional information: NHS England and NHS Improvement Regional Offices: please cascade this alert to community pharmacy.

Alert reference: SDA/2020/010

Action underway deadline: 02-Jun-2020

Action complete deadline: 30-Nov-2020

Attachments:

Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency